Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?

Abstract

The induction of HIV-1 broadly neutralizing antibodies (bnAbs) remains the primary goal of a preventive HIV-1 vaccine but no HIV-1 vaccine candidate has succeeded in inducing bnAbs. All the bnAbs isolated from chronically HIV-1 infected subjects display one or more traits associated with control by host tolerance and immunoregulatory mechanisms, including reactivity against self antigens. Recent studies on a HIV-1 patient with concurrent systemic lupus erythematosus have informed on how similar bnAbs are to typical autoantibodies controlled by immune tolerance mechanisms. Future studies aimed at elucidating the intersection between autoantibodies generated in the context of systemic lupus erythematosus and the development of HIV-1 bnAbs will further our knowledge of specific roadblocks that hamper the production of bnAbs and, ultimately, inform us on how to implement vaccine strategies to circumvent them.

• Authors: Mattia Bonsignori
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 13 Issue 11 Pg. 1271-3 (Nov 2014) ISSN: 1744-8395 [Electronic] England
• PMID: 25017952 (Publication Type: Editorial, Research Support, N.I.H., Extramural)

Chemical References

• AIDS Vaccines
• Antibodies, Neutralizing
• Autoantibodies
• HIV Antibodies

Topics

• AIDS Vaccines (immunology, isolation & purification)
• Antibodies, Neutralizing (blood)
• Autoantibodies (blood)
• HIV Antibodies (blood)
• HIV Infections (prevention & control)
• HIV-1 (immunology)
• Humans
• Immune Tolerance
• Lupus Erythematosus, Systemic (immunology)